News

Pemazyre is the first and only FDA-approved treatment for this indication, which was approved under accelerated approval based on overall response rate and duration of response (DOR). Continued

The regulator has approved Tukysa in combination with trastuzumab and capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who

Iksuda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology, ConjuALL, including LCB’s cancer-selectively activated payloads as well as its proprietary linker and conjugation platform, to research, develop

SPL7013 inhibited the infection of cells with the SARS-CoV-2 virus and the finding was validated by replicate testing against a positive control compound, remdesivir (Gilead), which is considered

According to the agreement, Moderna will use BARDA’s funding to advance its mRNA-1273 vaccine candidate to FDA licensure. The mRNA-1273 is a vaccine candidate against SARS-CoV-2 encoding for

ONTRUZANT is available in both 150 mg single-dose vials and 420 mg multiple-dose vials. ONTRUZANT will be introduced in the U.S. at a list price (wholesaler acquisition cost)

FT-4202 is a potent activator of pyruvate kinase-R (PKR) that, in preclinical studies, demonstrated the potential to beneficially impact both anemia and vaso-occlusive crises for people living with

The deal is said to leverage TScan’s advanced platform to discover novel cancer antigens, which are expected to be targeted by TCR-based therapies. TScan chief scientific officer Gavin

The Chinese biopharmaceutical company said that it has been developing the COVID-19 vaccine candidate since January 2020. The firm claimed that its scientists have quickly completed comprehensive preclinical